EU approves Bayer's new long-term contraceptive: firm

German drug maker Bayer said on Wednesday that European Union authorities had given the go-ahead for a new contraceptive which can prevent pregnancies for up to three years.

Bayer said in a statement that its healthcare division "has successfully concluded the European registration procedure for its new low dose -releasing intrauterine system (IUS)."

IUS is "a long-term placed in the uterus for the prevention of pregnancy for up to three years."

First launches of the product—which will be marketed under the name "Jaydess"—are expected in the second quarter of 2013 in the EU, the statement said.

Bayer also applied for US marketing authorisation for the product in December 2011.

add to favorites email to friend print save as pdf

Related Stories

Bayer rules out increasing bid for Schiff Nutrition

Nov 20, 2012

German chemicals and pharmaceuticals giant Bayer withdrew from a battle to buy US-based Schiff Nutrition International on Tuesday, ruling out an increase to its bid against a rival counter offer.

ACOG: Intrauterine device insertion linked to weight loss

May 07, 2012

(HealthDay) -- Women who undergo postpartum or interval insertion of Levonorgestrel-releasing Intrauterine System (LNG-IUS) or Copper T 380A (CU-T) intrauterine devices experience weight loss in the two years ...

Bayer unveils a faster-acting aspirin

May 29, 2011

Bayer AG is looking for a speedy remedy for stagnant aspirin sales. The company is introducing a reformulated aspirin today that works in half the time of its regular aspirin.

Recommended for you

Boxed warnings are common in novel therapeutics

Aug 19, 2014

(HealthDay)—Boxed warnings are common on recent drug approvals, and many occur years after approval, according to a research letter published online Aug. 15 in JAMA Internal Medicine.

AstraZeneca says DOJ closes probe into drug trial

Aug 19, 2014

British drugmaker AstraZeneca says the U.S. Department of Justice has closed its investigation into a clinical trial of the company's blood thinner Brilinta, and plans no further action.

Perampanel for epilepsy: Still no proof of added benefit

Aug 19, 2014

The drug perampanel (trade name Fycompa) has been approved since July 2012 as adjunctive ("add-on") therapy for adults and children aged 12 years and older with epileptic fits (seizures). In a new early benefit assessment ...

User comments